← Apogee Therapeutics, Inc. Common Stock overview

Apogee Therapeutics, Inc. Common Stock vs Abcellera Biologics: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Apogee Therapeutics, Inc. Common Stock (APGE)

Q3 2026
▲3▼1

AbbVie's $10.9B Apogee Buy Moves Toward Close, Funding Debt

  • AbbVie to acquire Apogee for $10.9B cash AbbVie agreed to buy Apogee for $10.9 billion in cash, a premium to the market price. This is the main reason APGE trades near the deal value. The deal is expected to close in the third quarter, so APGE's price is now tied to deal completion, not independent drug news.

    This is the core event that determines APGE's price now.

  • AbbVie funds deal with debt, preserving dividend AbbVie will pay for Apogee entirely with debt, not cash on hand, so its dividend remains safe. This reduces any risk that financing problems could delay or derail the deal. For APGE holders, it means the agreed cash price is more likely to be paid as planned.

    Shows the deal is well-financed, lowering risk to APGE's takeover price.

  • AbbVie's strong immunology growth supports deal rationale AbbVie raised its 2026 revenue outlook to $67.6 billion and said its Skyrizi and Rinvoq drugs are growing fast. Apogee's eczema drug zumilokibart fits into that immunology pipeline. Strong buyer performance makes it more likely AbbVie completes the purchase and invests in the asset.

    Confirms the buyer's health and strategic need for Apogee, supporting deal certainty.

  • Deal dilutes AbbVie EPS, but APGE unaffected AbbVie lowered its 2026 earnings guidance by about 14 cents per share because of the Apogee acquisition, and its stock dipped. This is a cost to AbbVie, not Apogee. APGE's agreed cash price does not change, so this does not hurt APGE's takeover value.

    Addresses the main negative headline and clarifies it does not reduce APGE's deal price.

July 2026
▲3▼1

AbbVie's $10.9B Apogee Buy Moves Toward Close, Funding Debt

  • AbbVie to acquire Apogee for $10.9B cash AbbVie agreed to buy Apogee for $10.9 billion in cash, a premium to the market price. This is the main reason APGE trades near the deal value. The deal is expected to close in the third quarter, so APGE's price is now tied to deal completion, not independent drug news.

    This is the core event that determines APGE's price now.

  • AbbVie funds deal with debt, preserving dividend AbbVie will pay for Apogee entirely with debt, not cash on hand, so its dividend remains safe. This reduces any risk that financing problems could delay or derail the deal. For APGE holders, it means the agreed cash price is more likely to be paid as planned.

    Shows the deal is well-financed, lowering risk to APGE's takeover price.

  • AbbVie's strong immunology growth supports deal rationale AbbVie raised its 2026 revenue outlook to $67.6 billion and said its Skyrizi and Rinvoq drugs are growing fast. Apogee's eczema drug zumilokibart fits into that immunology pipeline. Strong buyer performance makes it more likely AbbVie completes the purchase and invests in the asset.

    Confirms the buyer's health and strategic need for Apogee, supporting deal certainty.

  • Deal dilutes AbbVie EPS, but APGE unaffected AbbVie lowered its 2026 earnings guidance by about 14 cents per share because of the Apogee acquisition, and its stock dipped. This is a cost to AbbVie, not Apogee. APGE's agreed cash price does not change, so this does not hurt APGE's takeover value.

    Addresses the main negative headline and clarifies it does not reduce APGE's deal price.

Latest
▲3▼1

AbbVie's $10.9B Apogee Buy Moves Toward Close, Funding Debt

  • AbbVie to acquire Apogee for $10.9B cash AbbVie agreed to buy Apogee for $10.9 billion in cash, a premium to the market price. This is the main reason APGE trades near the deal value. The deal is expected to close in the third quarter, so APGE's price is now tied to deal completion, not independent drug news.

    This is the core event that determines APGE's price now.

  • AbbVie funds deal with debt, preserving dividend AbbVie will pay for Apogee entirely with debt, not cash on hand, so its dividend remains safe. This reduces any risk that financing problems could delay or derail the deal. For APGE holders, it means the agreed cash price is more likely to be paid as planned.

    Shows the deal is well-financed, lowering risk to APGE's takeover price.

  • AbbVie's strong immunology growth supports deal rationale AbbVie raised its 2026 revenue outlook to $67.6 billion and said its Skyrizi and Rinvoq drugs are growing fast. Apogee's eczema drug zumilokibart fits into that immunology pipeline. Strong buyer performance makes it more likely AbbVie completes the purchase and invests in the asset.

    Confirms the buyer's health and strategic need for Apogee, supporting deal certainty.

  • Deal dilutes AbbVie EPS, but APGE unaffected AbbVie lowered its 2026 earnings guidance by about 14 cents per share because of the Apogee acquisition, and its stock dipped. This is a cost to AbbVie, not Apogee. APGE's agreed cash price does not change, so this does not hurt APGE's takeover value.

    Addresses the main negative headline and clarifies it does not reduce APGE's deal price.

Q2 2026
▲2

AbbVie's $10.9B buyout of Apogee lifts APGE near offer price

  • AbbVie acquisition at $135.11/share AbbVie agreed to buy Apogee for $10.9 billion in cash, or $135.11 per share, a 49–60% premium. The deal centers on Apogee's phase-two eczema drug zumilokibart, which analysts think could rival Dupixent.

    This is the main event that drove APGE's price during the period.

  • All-cash deal funded from AbbVie's cash flow AbbVie can pay for the all-cash deal from its operating cash flow, making the payout more certain for Apogee shareholders. However, the deal won't add to AbbVie's earnings until 2032.

    Explains why the offer price is credible and supports APGE's price near the offer.

  • Board investigation adds deal risk A board investigation by Brodsky & Smith into whether Apogee ran a fair sales process adds risk. A lawsuit or higher bid could delay or alter the $135.11 payout, creating uncertainty for shareholders.

    This is a real counterweight that could affect whether the deal closes as planned.

  • APGE trades near offer price, upside capped APGE trades near the offer price, capping further upside unless a competing bid emerges. The stock is unlikely to rise much above $135.11 without a rival offer.

    Describes the current trading dynamic and limits to further gains.

June 2026
▲2

AbbVie's $10.9B buyout of Apogee lifts APGE near offer price

  • AbbVie acquisition at $135.11/share AbbVie agreed to buy Apogee for $10.9 billion in cash, or $135.11 per share, a 49–60% premium. The deal centers on Apogee's phase-two eczema drug zumilokibart, which analysts think could rival Dupixent.

    This is the main event that drove APGE's price during the period.

  • All-cash deal funded from AbbVie's cash flow AbbVie can pay for the all-cash deal from its operating cash flow, making the payout more certain for Apogee shareholders. However, the deal won't add to AbbVie's earnings until 2032.

    Explains why the offer price is credible and supports APGE's price near the offer.

  • Board investigation adds deal risk A board investigation by Brodsky & Smith into whether Apogee ran a fair sales process adds risk. A lawsuit or higher bid could delay or alter the $135.11 payout, creating uncertainty for shareholders.

    This is a real counterweight that could affect whether the deal closes as planned.

  • APGE trades near offer price, upside capped APGE trades near the offer price, capping further upside unless a competing bid emerges. The stock is unlikely to rise much above $135.11 without a rival offer.

    Describes the current trading dynamic and limits to further gains.

▼1

Apogee's $135.11 AbbVie buyout holds, but board probe adds risk

  • Board investigation could delay or reduce deal payout Brodsky & Smith is investigating whether Apogee's board ran a fair sales process and got a fair price. If the probe leads to a lawsuit or a higher bid, the $135.11 cash payout could be delayed or changed, which is a risk for shareholders waiting for the deal to close.

    This is the only new event that could actually change the deal terms or timing, directly affecting APGE's price.

▲3

AbbVie's $10.9B cash buyout locks in a big premium for Apogee

  • AbbVie agrees to buy Apogee for $10.9 billion in cash AbbVie will pay $135.11 per share in cash, a roughly 49-60% premium to Apogee's prior close. That fixed price is now the main driver: APGE trades near it, and the deal caps further upside unless a higher bid emerges.

    This is the definitive event that sets APGE's price and explains the period's move.

  • Apogee's eczema drug zumilokibart is the strategic prize The lead drug, in phase two testing, could rival blockbuster Dupixent for atopic dermatitis. Analysts say strong data and scarce immunology assets justify the premium, supporting the deal price and making a rival bid possible.

    It explains why AbbVie is paying up and why the buyout price is credible.

  • AbbVie can fund the all-cash deal without new debt AbbVie will use operating cash flow, so the buyout is not at risk from financing. That makes the $135.11 cash payout more certain for Apogee holders, though AbbVie says the deal won't add to earnings until 2032.

    Financing certainty supports the deal closing and the cash value to APGE holders.

Abcellera Biologics Inc (ABCL)

Q3 2026
▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

  • Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.

    This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.

  • Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.

    This is a new financial report showing deteriorating results, which weighs on the stock price.

  • ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.

    This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

July 2026
▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

  • Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.

    This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.

  • Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.

    This is a new financial report showing deteriorating results, which weighs on the stock price.

  • ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.

    This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

Latest
▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

  • Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.

    This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.

  • Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.

    This is a new financial report showing deteriorating results, which weighs on the stock price.

  • ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.

    This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

© 2026 MarketDXWhy